This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Aug;56(2):399-400.

doi: 10.1016/j.eururo.2009.05.036.

Re: Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer

Fray F Marshall¹

Affiliations

PMID: 19691139
DOI: 10.1016/j.eururo.2009.05.036

Comment

Re: Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer

Fray F Marshall. Eur Urol. 2009 Aug.

. 2009 Aug;56(2):399-400.

doi: 10.1016/j.eururo.2009.05.036.

Author

Fray F Marshall¹

Affiliation

¹ Department of Urology, Emory University School of Medicine, Atlanta, GA, USA. fmarsha@emory.edu

PMID: 19691139
DOI: 10.1016/j.eururo.2009.05.036

No abstract available

PubMed Disclaimer

Comment on

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ. Gollob JA, et al. J Clin Oncol. 2007 Aug 1;25(22):3288-95. doi: 10.1200/JCO.2007.10.8613. J Clin Oncol. 2007. PMID: 17664476 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science